STOP-HCV is a Medical Research Council (MRC) funded consortium which aims to use patient information to establish the most effective and cost effective treatments for patients with Hepatitis C Virus.
The STOP-HCV consortium is formed of 21 partners representing academia, industry and the Hepatitis C Trust.
Vaccines & Infectious Disease Event, 6 March 2015 - STOP-HCV is taking part in this free event at the Oxford University Museum of Natural History. The event is suitable for GCSE and A-Level students and anyone with an interest in learning more about immunity and disease prevention.
Gilead Sciences BOSON trial - the Clinical Research Network's 'Spotlight on hepatitis research' highlights the importance of the academic-industrial collaboration within STOP-HCV.
STOP-HCV award now active
The official start date for STOP-HCV was 16th September 2013. Work has now begun to meet the consortiums aims.